Floatz logo

Ribociclib

HER2 Positive Breast Carcinoma

Danish Breast Cancer Cooperative GroupSmall moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
89/ 100

Competitive context

175 Active assets in the HER2 Positive Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Pertuzumab
SWOG Cancer Research Network
Phase 4BB
Trastuzumab
SWOG Cancer Research Network
Phase 4BB
Docetaxel
Ohio State University Comprehensive Cancer Center
Phase 3BB
Cyclophosphamide
National University Hospital, Singapore
Phase 3BB
Vinorelbine Ditartrate
Fudan University
Phase 3BB

View all 50 →

Same molecule, other indications

Ribociclib is also rated in:

hormone receptor-positive breast cancerActive
BBB
Indicative · Phase 4
73 / 100
View asset →
breast cancerActive
BB
Indicative · Phase 4
70 / 100
View asset →
estrogen-receptor positive breast cancerActive
BB
Indicative · Phase 3
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →